UPDATE 1-Aduro IPO pricing values drugmaker at $1 bln

April 14, 2015 10:23 PM

14 0

April 14 (Reuters) - Aduro Biotech Inc's initial public offering has been priced at $17 per share, an underwriter said, valuing the cancer immunotherapy drug developer at about $1 billion.

The upsized offering, which was priced on par with the company's expectation, raised about $119 million.

Also read: Bratz Maker Plans Toys ‘R’ Us Bid Despite Small Crowdfunding Raise

Read more

To category page